Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
degenerativas de la retina
Presentacin Sociedad Argentina de Retina
y Vtreo
Abril 2016
CARGO
Dr PERDOMO
Strasbourg
Edad de aparicin
Distrofias retinianas/ de la infancia
Fenotipos tardos
?
Caso espordico/ familiar
http://www.iscev.org/standards
Lower ERG amplitudes and longer peak
times generally apply below 612 months
of age under dark-adapted conditions, and
below 23 months of age under light-
adapted conditions. Below 6 months of
age, the Dark-adapted 3 ERG may be poorly
defined in healthy infants; Dark-adapted
10 ERGs are usually well defined in infants
without retinal disease at all ages.
PERG/ mfERG
ERG
PERG
mfERG
Standardization of ERG reporting is critical to the goal of having comparable data
worldwide.
EOG: Electrophysiology of the outer retina in dark and light.
PERG
Normal P50/
Abnormal P50
Abnormal N95
ERG
62 gnes de RP :
(50% des cas muts)
24 AD
RHO : 20-30%
36 AR
USH2A : 10-15%
ABCA4 : 2-5%
2 LX
Amaurose congnitale de Leber NOL
1869/ Theodor Karl Gustav von Leber/ Allemagne
phnotype + svre et prcoce de DR, congnital
Dg: 1er. Anne de vie
Origine gntique: AR, affect. Rare
Htrognit gntique (22 gnes/2015) et phnotypique
TC: AV , nystagmus, RPMs alt / absents, signe oculo- digitale de Franceschetti,
photophobie, hypermtropie majeure, kratocne
FO: normal / poivre et sel/ RP, etc
Corrlation G/Ph: colobome maculaire: AIPL1, RDH12, NMNATI1,
dpts punctiformes blanchtres et atrophie maculaire stellaire
RPE65, preserved para-arteriolar RPE CRB1
ERG: / absence totale de rponses
ACL
NMNAT1
Koenekoop et al. (2012) reexamined affected individuals from 8 families with Leber congenital amaurosis in whom they had identified
mutations in the NMNAT1 gene (608700), which is ubiquitously expressed. All individuals with biallelic NMNAT1 mutations had severe
LCA but otherwise normal physical and mental health. However, in addition to the typical LCA phenotype all patients were found to have a
peculiar, prominent retinal feature termed 'macular coloboma,' which consists of an atrophic lesion in the central retina with a pigmented
border, signifying complete loss of neural tissue in the fovea, including photoreceptors, bipolar cells, and ganglion cells. Based on these
findings, Koenekoop et al. (2012) suggested that NMNAT1 mutations are associated with severe and rapid foveal degeneration.
ACL
RD3
Friedman et al. (2006) found that mouse Rd3 is preferentially expressed in the retina and
exhibits increasing expression through early postnatal development
ACL
RDH12
Vm 2. 0
viD
-0.4 -0.4
0.4 0.4
b
0 0 3-OP [OD] 4-OP [OS] 0 0 0 0 0 b 0
b b
ms-20 0 20 40 60 80 100 ms-20 0 20 40 60 80 100 b b Peak
Peak
a a a a a
a Trough Trough
Vm 2. 0
viD
Vm 2. 0
viD
-0.4 -0.4
-0.2 -0.2 -0.2 -0.2 -50 -50 -50 -50
-0.2 -0.2
a ba
b
0 0
-0.4 -0.4 -0.4 -0.4 -100 -100 -100 -100
0.2 0.2
0.2mV
0.2mV
0.4 0.4
0.2mV
0.2mV
50V
50V
50V
50V
Div
Div
Div
Div
Div
Div
Div
Div
1 [OD] 2 [OS]
ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 20 40 60 80 100 ms 0 20 40 60 80 100 ms-20 0 20 40 60 80 100 ms-20 0 20 40 60 80 100
CEP290
1-Chan 1 [OS]
40
20
0 1(OS)
2(OS)
B
B
A A
-20
-40
20V
Div
200 0.2
0 200
-0.2 B
0.2mV
100 A
100
-0.4
Div
0.2mV
A
100V
-0.4
Div
Div
Div
ms 0 50 100 150 200 250ms 0 50 100 150 200 250 ms 0 50 100 150 200 250
2-Chan 2 [OD] 3-Virt.Chan1 [OS] 2-Chan 2 [OD]
100
200 50
200
0
-50
100 100
50V
-100
Div
0 B
ms 0 50 100 150 200 250 0 B
A 4-Virt.Chan2 [OD]
100
-100 50 -100
0 A
-200 -50 -200
100V
100V
50V
-100
Div
Div
Div
ms 0 50 100 150 200 250ms 0 50 100 150 200 250 ms 0 50 100 150 200 250
0.2mV
100V
100V
50V
Div
Div
Div
Div
ms 0 50 100 150 200 250ms 0
2-Chan 2 [OD]
50 100 150 200 ms 0 250 50 100 150 200 250 ms 0 25 50 75 100
2-Chan 2 [OD] 2-Chan 2 [OD] 2-Chan 2 [OD]
0.2mV
100V
100V
50V
Div
Div
Div
Div
ms 0 50 100 150 200 250ms 0 50 100 150 200 ms 0 250 50 100 150 200 250 ms 0 25 50 75 100
200 200
100 100
-100
1(OS) 0
-100
1(OS)
A
B
-200 -200
100V
100V
Div
Div
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250
2-Chan 2 [OD] 2-Chan 2 [OD]
100 100
0 1(OD) 0 1(OD)
-200
-100
-200
A
B
100V
100V
Div
Div
ms
200
0 50 100 150 100
200 250 ms 0 50 100 150 200 250
100 50
0 1(OS) 0 1(OS) B
B
A A
-200 -100
100V
50V
Div
Div
ms 0 50 100 150 200 250 ms 0 25 50 75 100
2-Chan 2 [OD] 2-Chan 2 [OD]
100 50
0 1(OD)
0 1(OD)
B
A B
A
-100 -50
-200 -100
100V
50V
Div
Div
ms 0 50 100 150 200 250 ms 0 25 50 75 100
RP lie lX
XY XX
RPGR
RP2
XY XY
II II
II II
EMC y RP
RP sans pigment
Dbut des signes 13 ans
AV : OD 4/10e P10; OG 10/10e P1,5
ERG : teint droite et normal gauche.
Dystrophie de cnes avec hyper- rponse des btonnes
KCNV2 /A.R
1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS]
1 [OD] 2 [OS] 1 [OD] 2 [OS]
0.4
B
200 300 200 0.2 200 B
B 0 B
0 100 0 0
B ms 0 50 100 150 200 250
2-Chan 2 [OD]
-100 0 -100 0.4 -100
A 0.2 50 50 50 50
A
-200 -100 -200 0 B
-200
100V
100V
-0.2 b
100V
100V
0.2mV
1(OS)
Div
Div
b
-0.4 A 1(OD)
Div
A 3A(OD)
Div
2(OD) 3A(OS)
Div
2(OS)
ms 0 50 100 150 200 250
ms 0 50 100 150 200 ms
250 2-Chan 2 0[OD] 50 100 150 200 250 Peak Peak 2(OS)
250 ms 0 50 100 150 200 250 0 0 0 1(OD) 0 3A(OS)
2-Chan 2 [OD] 2-Chan 2 [OD] ms 0 50 100 150 200 2-Chan 2 [OD]
3A(OD)
2(OD) 1(OS)
3-Virt.Chan1 [OS]
100
200 300 200 B B Trough a
50 200 Trough a
0
100 200 100 -50 -50 -50 -50 -50
B 100
50V
-100
Div
0 100 0
B 0
ms 0 50 100 150 200 250
-100 0 -100 4-Virt.Chan2 [OD]
A 100 -100 -100 -100 -100 -100
A
50
-200 -100 -200 0
100V
-200
100V
100V
-50
100V
Div
Div
Div
50V
50V
50V
50V
50V
-100 A
Div
Div
Div
Div
Div
Div
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0
ms 0 50 100 150 200 250 20 40 60 80 100 ms 0 20 40 60 80 ms
100-20 0 20 40 60 80 100 ms-20 0 20 40 60 80 100
ABCA4
Stargardt
II II
RDS
RP
II II
Rtinoschisis lie lX
1 [OD] 2 [OS] 1 [OD] 2 [OS] 1 [OD] 2 [OS] 1 [OD] 2 [OS] 1 [OD] 2 [OS]
0.4 0.4
200 200
200 200 0.2 0.2 100 100 100 100
0 0
100 100
b b
-0.2 -0.2
100 100 a
50 50 50 50
a
b
-0.4 -0.4
0.2mV
0.2mV
Peak Peak b b
0 0
Div
Div
0 0
O1 O2 O1 O2
-200 -200
-200 -200 -20 -20 -100 -100 -100 -100
a
a
-40 -40
100V
100V
100V
100V
-300 -300
50V
50V
50V
50V
20V
20V
Div
Div
Div
Div
Div
Div
Div
Div
Div
Div
ms 0 50 100 150 200 ms 0 50 100 150 200 ms-20 0 20 40 60 80 100 ms-20 0 20 40 60 80 100 ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 20 40 60 80 100 ms 0 20 40 60 80 100 ms-20 0 20 40 60 80 100 ms-20 0 20 40 60 80 100
P/ I. Rtinoschisis lie lX
Goldmann
Favre
NR2E3/ AR
200 200
0 0
A B
-100 B
-100 50 50
50 50
-200 -200 A b
100V
100V
Div
Div
ms 0 0
0 50 100 150 200 250 ms 0 50 100 150 200 250 0 0 b Peak
Peak
2-Chan 2 [OD] 2-Chan 2 [OD] Trough
Trough
200 200
a
a
100 -50 -50 -50 -50
100
0 0
A B
-100 -100
B
-100 -100 -100 -100
A
-200 -200
100V
100V
50V
50V
50V
50V
Div
Div
Div
Div
Div
Div
XY XX
XY XY
Bietti/CYP4V2/ 4q35.2/AR
Gyrate atrophy of choroid and
retina with or without
ornithinemia/ OAT/ 10q26.13
Suspicion Sorsby
Sorsby fundus
22q12.3 136900 AD 3 TIMP3 188826
dystrophy
TOPORS
Gene
AD
Mutations in TOPORS Cause Autosomal Dominant Retinitis Pigmentosa with Perivascular Retinal
Pigment Epithelium Atrophy
Christina F. Chakarova,* Myrto G. Papaioannou,* Hemant Khanna, Irma Lopez, Naushin Waseem, Amna Shah, Torsten Theis, James Friedman, Cecilia
Maubaret, Kinga Bujakowska, Brotati Veraitch, Mai M. Abd El-Aziz, De Quincy Prescott, Sunil K. Parapuram, Wendy A. Bickmore, Peter M. G. Munro,
Andreas Gal, Christian P. Hamel, Valeria Marigo, Chris P. Ponting, Bernd Wissinger, Eberhart Zrenner, Karl Matter, Anand Swaroop, Robert K.
Koenekoop, and Shomi S. Bhattacharya W
The American Journal of Human Genetics Volume 81 November 2007
CTRP5
(C1QTNF5) gene
0.4 0.4
200 200 0.2 0.2 200 200 100 100 100 100
0 b 0 b
b
-0.2 a -0.2 a
50 50 50 50
100 b 100 100 100
b
b
-0.4 -0.4
0.2mV
0.2mV
Peak Peak
Div
Div
40 40 Trough
Trough
-100 -100 -100 -100 -50 a -50 -50 -50
20 20
a
a a
0 0
O1 O2 O1 O2
-200 -200 -20 -20 -200 -200 -100 -100 -100 -100
-40 -40
100V
100V
100V
100V
50V
50V
50V
50V
20V
20V
Div
Div
Div
Div
Div
Div
Div
Div
Div
Div
0 0 0 0 0 0
100V
100V
100V
50V
50V
Div
Div
Div
Div
Div
Div
ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 50 100 150 200 ms 0 20 40 60 80 100 ms 0 20 40 60 80 100
Cockayne syndrome (CS) is characterized by growth failure and multisystemic degeneration, with a variable
age of onset and rate of progression
ERCC6
ERCC8
Both play important roles in transcription-coupled
nucleotide excision repair (TC-NER), a DNA repair
process that preferentially removes UV-induced
pyrimidine dimers and other transcription-blocking
lesions from the transcribed strands of active
genes
Major criteria
Postnatal growth failure (height and weight <5th centile by age 2 years)
Progressive microcephaly and neurologic dysfunction manifested as early
developmental delay in most individuals, followed by progressive behavioral and
intellectual deterioration in all individuals; brain MRI reveals leukodystrophy
[Boltshauser et al 1989, Sugita et al 1992]. Intracranial calcifications are seen in some
individuals.
Minor criteria
Cutaneous photosensitivity with or without thin or dry skin or hair (~75%)
Demyelinating peripheral neuropathy diagnosed by electromyography, nerve
conduction testing, and/or nerve biopsy
Pigmentary retinopathy (~55%) and/or cataracts (~36%)
Sensorineural hearing loss (~60%)
Dental anomalies, including dental caries (~86%), enamel hypoplasia, anomalies of
tooth number and anomalies of tooth size and shape
A characteristic physical appearance of "cachectic dwarfism" with thinning of the
skin and hair, sunken eyes, and a stooped standing posture
Characteristic radiographic findings of thickening of the calvarium, sclerotic
epiphyses, vertebral and pelvic abnormalities
Usher syndrome type I is characterized by congenital, bilateral, profound sensorineural hearing loss, vestibular areflexia,
and adolescent-onset retinitis pigmentosa. Unless fitted with a cochlear implant, individuals do not typically develop
speech. MYO7A (USH1B), USH1C, CDH23 (USH1D), PCDH15 (USH1F), USH1G, and CIB2 (USH1J)
Usher syndrome type II is characterized by congenital (i.e., prelingual) bilateral sensorineural hearing loss that is mild to
moderate in the low frequencies and severe to profound in the higher frequencies, intact vestibular responses, and
retinitis pigmentosa (RP). USH2A (accounting for up to 80% of cases), GPR98 (VLGR1), and DFNB31.
Usher syndrome type III (USH3). USH3 is characterized by postlingual progressive sensorineural hearing loss, late-onset
RP, and variable impairment of vestibular function [Plantinga et al 2005]. Mutation of CLRN1 or HARS is causative [Joensuu
et al 2001, Vstinsalo et al 2011, Puffenberger et al 2012]. Persons with USH3 may have symptoms that mimic USH2,
especially early in the progression of the disease [Pennings et al 2003].
Enf. de Refsum
Anosmie
RP prcoce
Neuropathie Sensorielle/motrice
Surdit de perception
Ataxie
Ichtyose
Cardiomyopathie
Dg +: clinique/ biologique: concentration plasmatique de Ac.
phitanique 200 mol/L
AR/ 2 gnes PHYH et PEX7
S. Dltion de lADNm
Kearn Sayre S. (KSS)/ Pearson S./
ophtalmoplgie externe progressive (PEO)
KSS
Pathologie multi systmique
Triade: dbut < 20a, RP, ptosis, PEO (paralysies de
MExO)
1+ : troubles de la conduction cardiaque, ataxie
crbelleuse, protinorachie > 100 mg/dl
Kearn Sayre Syndrome
S. de Jalili Mutations in CNNM4 cause Jalili syndrome, consisting of autosomal-recessive cone-rod dystrophy and amelogenesis
imperfecta. Am J Hum Genet. 2009 Feb;84(2):266-73. doi: 10.1016/j.ajhg.2009.01.009. Epub 2009 Feb 5.
II II
II II
Infrared RE Infrared LE
FAF RE
FAF LE
Jalili Syndrome
1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS]
0.4
200 0.2 0.4 200 200
B 0 B
-0.2
100 100 100
0.2mV
A 0.2
-0.4
Div
0 ms 0 50 100 150 200 250 0 B 0 0
B B
A 2-Chan 2 [OD] A A
0.4
-100 -0.2 -100 -100
0.2 A
0 B
-200 -0.2 -0.4 -200 -200
100V
100V
100V
0.2mV
0.2mV
A
-0.4
Div
Div
Div
Div
Div
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 25 50 75 100 ms 0 50 100 150 200 250
2-Chan 2 [OD] 3-Virt.Chan1 [OS] 2-Chan 2 [OD] 2-Chan 2 [OD] 2-Chan 2 [OD]
100
200 50 0.4 200 200
B
0
-50
100 0.2 100 100
50V
-100
Div
0 ms 0 50 100 150 200 250 0 B 0 0
4-Virt.Chan2 [OD] A B A B
A 100
-100 -0.2 -100 -100
50 A
0
100V
100V
0.2mV
50V
-100
Div
Div
Div
Div
Div
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 25 50 75 100 ms 0 50 100 150 200 250
Dark-adapted 3 ERG
Dark-adapted
Dark-adapted 0,01 ERG oscillatory potentials Dark-adapted 10 ERG Light- adapted 3 ERG Light- adapted 31,25 Hz Flicker ERG
ERG
1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS] 1-Chan 1 [OS]
0.4
400 0.2 0.2
200 200
B 0 1(OS) B B
300 -0.2 0 1(OS)
0.2mV
100 100
-0.4
Div
A B B
200 -0.2 2(OS)
ms 0 50 100 150 200 250 0 1(OS) 0
2-Chan 2 [OD]
100 0.4 -0.4 A A
A -100 -100
0.2
0 1(OS) 0 1(OD) B
-0.6
-0.2 -200 -200
100V
0.2mV
100V
100V
0.2mV
A -0.4
Div
-100 -0.8
Div
Div
Div
Div
A
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 25 50 75 100 ms 0 50 100 150 200 250
2-Chan 2 [OD] 3-Virt.Chan1 [OS] 2-Chan 2 [OD] 2-Chan 2 [OD] 2-Chan 2 [OD]
100
400 B 50 0.2
200 200
0 1(OS) B
300 -50 0 1(OD)
100 B 100
50V
-100
Div
2(OD) B
200 -0.2
ms 0 50 100 150 200 250 0 1(OD) 0
4-Virt.Chan2 [OD]
100 100 -0.4 A
50 -100 A -100
A
0
1b
1(OD)
0 1(OD) -0.6
-50 -200 -200
100V
100V
100V
0.2mV
50V
A -100
Div
-100 -0.8
Div
Div
Div
Div
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 25 50 75 100 ms 0 50 100 150 200 250
Full field ERG (ISCEV protocols) showed mild reduced rod-driven response. Marqued reduction of cone
system response was present at light adapted ERG. ERG confirmed the diagnosis of cone-rod dystrophy
classically associated in the context of Jalili Syndrome.
1a Jalili patient ERG, 1b normal ERG
Pas tjs gntique.
100 100
-0.4 100 100
Div
0 1(OS)
ms 0 1(OS) B
B
0 50 100 150 200 250
A 2-Chan 2 [OD] A
-100 0.4 -100
0.2 50 50
50 50
0 1(OD)
-200 -200
-0.2 B b
100V
A
100V
b
0.2mV
-0.4
CAR
Div
Div
Peak
Div
Peak
0 0
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0
2-Chan 2 [OD]
50 100 150 200 250 0 0
2-Chan 2 [OD] 3-Virt.Chan1 [OS]
100 a a
-100
Div
0 1(OD) 0 1(OD)
B ms 0 50 100 150 200 250 B
A 4-Virt.Chan2 [OD] A
100 -100 -100 -100
-100 -100 -100
50
0 1(OD) -200
-200
100V
-50
100V
50V
50V
50V
Div
-100
50V
50V
Div
Div
Div
Div
Div
Div
ms 0 50 100 150 200 250 ms-20 0 20 40 60 80 100 ms-20 0 20 40 60 80 100
ms 0 50 100 150 200 250 ms 0 50 100 150 200 250 ms 0 20 40 60 80 100 ms 0 20 40 60 80 100
100 100
1(OS)
0 0
ms 0 50 100 150 200 250 0
A B 2-Chan 2 [OD]
0.4
-100 a B
-100
-100 A
B
0.2 50 50
0 50 50
b
-200 -200
-0.2 A B
-200
100V
100V
100V
0.2mV
-0.4
Div
Div
Div
a
ms 0 50 100 150 200 250 ms 0 50 100
100 150
150 200
200 250 ms
250 0 50 100 150 200 250 0 0
0 Peak 0 Peak
2-Chan 2 [OD] 2-Chan 2 [OD]
3-Virt.Chan1 [OS] 2-Chan 2 [OD]
Trough
100 Trough
200 50
200 200
MAR
0
-50 -50 -50 -50 -50
100 100 100
50V
-100 b
a
Div
0 0
ms
1(OD)
0 50 100 150 200 250 0
A B 4-Virt.Chan2 [OD]
100 -100 -100
-100 -100 a B -100 B -100 -100
50 A
0
-200 -200
-50 -200
100V
100V
100V
50V
50V
50V
-100
50V
50V
Div
Div
Div
Div
Div
Div
Div
Div
La prsence des Ac. anti-rtine circulants nest pas spcifique et ne suffit pas
pour faire le Dg.
(autres pathologies rtiniennes, maladies auto-immunes systmiques, sujets normaux)
Baisse de lacuit visuel (+/- aigue)/ normal
Scotomes
PHOTOPSIES
Nyctalopie
photophobie
Dyschromatopsie
Fundus: normal/ EPR alt., pleur papillaire, vaisseaux grles
Bilatrale mais parfois asymtrique
Inflammation minime voir absente
No PNAR: femme, adulte (50-60 ans), sans antec. opht, photopsies,
scotomes, sans antc familial de RP, ERG pathologique, absence de cancer
associ
RP pri - vasculaire ?
Champ visuel :
OD OG
A retener
Pathologies rares, souvent sous diagnostiques
Handicap visuel ccit lgale
Impact familial
Impact multi-systmique
Avis ophtalmo gntique conseill
Phnotypage clinique et fonctionnel
Gnotypage/ conseil gntique appropri
Dg antnatal (primplantatoire ou prnatale)
Traitement spcifique non disponible
Prise en charge de lhandicap visuel
Ttm pharmacologique
Cellules souches
Thrapie gnique
Implants rtiniens
Prise en charge multidisciplinaire
de formes syndromiques